Loading...
•
Sep 30, 2024
Jaguar Health Q3 2024 Earnings Report
Reported a 14% increase in combined net revenue for prescription and non-prescription products compared to Q2 2024, and an 11% increase compared to Q3 2023.
Key Takeaways
Jaguar Health reported a revenue of $3.1 million for Q3 2024, representing an increase of 14% compared to Q2 2024 and 11% compared to Q3 2023. The company is advancing its core programs, including the development of crofelemer and the commercial launch of Gelclair.
Combined net revenue for Q3 2024 reached approximately $3.1 million, a 14% increase over Q2 2024 and an 11% increase over Q3 2023.
Mytesi revenue was approximately $3.0 million in Q3 2024, representing an 8% increase over Q3 2023.
The company initiated the commercial launch of Gelclair® in October 2024.
Jaguar is initiating two Phase 2 trials in Q4 2024 and supporting multiple investigator-initiated proof-of-concept studies of crofelemer.
Forward Guidance
Jaguar Health anticipates catalysts in its core programs over the next 6 months, including the development of crofelemer and the commercial launch of Gelclair. The board of directors has no intention of implementing a reverse split of the Company’s common stock.
Positive Outlook
- Initiating two Phase 2 trials in Q4 2024.
- Supporting multiple investigator-initiated proof-of-concept studies of crofelemer.
- Results of IITs expected by the end of 2024 and throughout 2025.
- Ongoing U.S. commercial launch of Gelclair.
- No intention of implementing a reverse split of the Company’s common stock.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...